JLM019 / Jecho Biopharma - LARVOL DELTA

A Phase I Study of JLM019 Injection (clinicaltrials.gov) - P1 | N=115 | Recruiting | Sponsor: Jecho Biopharmaceuticals Co., Ltd.

New P1 trial • B Cell Lymphoma • Biliary Tract Cancer • Classical Hodgkin Lymphoma • Colorectal Cancer • Gastric Cancer • Head and Neck Cancer • Hematological Malignancies • Hepatocellular Cancer • Hodgkin Lymphoma • Lung Cancer • Lymphoma • Melanoma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • JAK1 • JAK2 • MSI • POLD1 • POLE

Persistent elimination of tumors via balanced regulation of immune signals (AACR 2025) - "Pre-clinical toxicity and PK/PD studies in cynomolgus monkey have shown a promising safety and toxicity profile, with a dose up to 100mg/kg being tolerated. These encouraging results prompted us to advance JLM019 for clinical studies in humans."

IO biomarker • Oncology • CD80 • CTLA4 • PD-L1 • PD-L2